DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma

Information source: Mayo Clinic
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Melanoma (Skin)

Intervention: MART-1 antigen (Biological); IL-2 (Biological); gp100 antigen (Biological); GM-CSF (Biological); MART-1a peptide (Biological)

Phase: Phase 1

Status: Active, not recruiting

Sponsored by: Mayo Clinic

Official(s) and/or principal investigator(s):
Svetomir Markovic, MD, PhD, Study Chair, Affiliation: Mayo Clinic

Summary

RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood. Aldesleukin may stimulate the white blood cells to kill tumor cells. Giving vaccine and different doses of GM-CSF mixed in incomplete Freund's adjuvant, with or without aldesleukin, may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and how well giving vaccine therapy together with GM-CSF, with or without low-dose aldesleukin, works in treating patients with stage II, stage III, or stage IV melanoma.

Clinical Details

Official title: Melanoma Peptide Vaccines (MART1 Analog, gp100 and Survivin) With GM-CSF and Low-Dose IL-2 as Immune Adjuvants, A Pilot Study

Study design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Percent changes in peptide vaccine-specific immune responses (tetramer frequencies) from pretreatment levels

Number and severity of hematologic and nonhematologic toxicities observed at each dose level

Secondary outcome:

Delayed-type hypersensitivity positivity

Maximum percent change in CD4, CD8, CD14, CD19, and C20 levels from preimmunization levels

Time to treatment failure

Time to progression

Detailed description: OBJECTIVES:

- Determine the safety and toxicity profile of peptide vaccine comprising MART-1 antigen,

gp100 antigen, and survivin antigen in combination with sargramostim (GM-CSF) emulsified in incomplete Freund's adjuvant (IFA) with or without low-dose aldesleukin in patients with stage II-IV melanoma.

- Determine the immunologic effects of two different doses of GM-CSF coemulsified with

melanoma peptides in IFA in these patients.

- Determine the immunological effects of low-dose aldesleukin therapy administered after

peptide immunization in these patients.

- Collect preliminary data on the impact of the vaccine on clinical outcomes in these

patients. OUTLINE: This is a pilot study. Patients are stratified according to disease stage (II vs III or IV). Patients are sequentially enrolled into 1 of 4 different dose schedules.

- Dose schedule 1: Patients receive gp100 antigen, MART-1 antigen, survivin antigen, and

sargramostim (GM-CSF) emulsified in incomplete Freund's adjuvant (peptide vaccine) subcutaneously (SC) on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.

- Dose schedule 2: Patients receive peptide vaccine as in group 1. Patients also receive

low-dose aldesleukin SC twice daily on days 7-20. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.

- Dose schedule 3: Patients receive peptide vaccine as in group 1 except with a higher

dose of GM-CSF. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.

- Dose schedule 4: Patients receive peptide vaccine as in group 1 except with a higher

dose of GM-CSF. Patients also receive low-dose aldesleukin SC twice daily on days 7-20. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 5 patients receive treatment at subsequent dose schedule until the maximum tolerated dose schedule (MTDS) is determined. The MTDS is defined as the dose schedule preceding that at which 2 of 5 patients experience dose-limiting toxicity within the first course. After completion of study therapy, patients are followed every 3 months for up to 2 years. PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

DISEASE CHARACTERISTICS:

- Histologically confirmed melanoma

- Stage II-IV disease

- Completely resected disease

- No known standard therapy that is potentially curative or proven capable of extending

life expectancy exists

- HLA-A2 positive

PATIENT CHARACTERISTICS:

- ECOG performance status 0-2

- Life expectancy ≥ 12 weeks

- ANC ≥ 1,500/mm³

- Hemoglobin > 10 g/dL

- Platelet count ≥ 50,000/mm³

- AST ≤ 3 times upper limit of normal (ULN)

- Alkaline phosphatase ≤ 3 times ULN

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No uncontrolled or current infection

- No known allergy to vaccine or immunoadjuvant components

- No known immune deficiency

PRIOR CONCURRENT THERAPY:

- No chemotherapy within the past 4 weeks and recovered

- No biologic therapy within the past 4 weeks

- No radiation therapy within the past 4 weeks

Locations and Contacts

Mayo Clinic, Rochester, Minnesota 55905, United States
Additional Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Starting date: March 2007
Last updated: March 23, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017